...
首页> 外文期刊>Lancet Neurology >Tracking atrophy progression in familial Alzheimer's disease: a serial MRI study.
【24h】

Tracking atrophy progression in familial Alzheimer's disease: a serial MRI study.

机译:追踪家族性阿尔茨海默氏病萎缩的进展:一项系列MRI研究。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

BACKGROUND: Serial MRI scanning of autosomal dominant mutation carriers for Alzheimer's disease provides an opportunity to track changes that could predate symptoms or clinical diagnosis of the disease. We used hierarchical modelling to assess how hippocampal and whole-brain volumes change as familial Alzheimer's disease progresses from the presymptomatic stage through to diagnosis. METHODS: Nine mutation carriers had serial clinical assessments and volumetric MRI scans (41 scans: range 3-8 per patient) at different clinical stages (presymptomatic, mild cognitive impairment, or clinical Alzheimer's disease). 25 healthy controls had serial scanning (54 scans: range 2-4 per patient) for comparison. We measured whole brain and total hippocampal volumes using semi-automated techniques, and adjusted for total intracranial volume. Hierarchical models were developed to estimate differences in volume and atrophy rate between mutation carriers and controls in relation to when the disease was clinically diagnosed. FINDINGS: Mutation carriers had significantly increased hippocampal and whole-brain atrophy rates compared with controls and these differences increased with time. Differences in hippocampal and whole-brain atrophy rates between controls and mutation carriers were evident 5.5 and 3.5 years, respectively, before diagnosis of Alzheimer's disease. At a cross-sectional level, differences in mean hippocampal volume between mutation carriers and controls became significant 3 years before clinical diagnosis, whereas differences in mean brain volumes became significant only 1 year before diagnosis. INTERPRETATION: Structural changes can be seen on MRI scans that predate the clinical onset of familial Alzheimer's disease. Longitudinal measures of atrophy rates can identify differences between mutation carriers and controls 2-3 years earlier than cross-sectional volumetric measures.
机译:背景:对常染色体显性突变携带者进行阿尔茨海默氏病的连续MRI扫描提供了跟踪可能早于该疾病的症状或临床诊断的变化的机会。我们使用分层模型来评估随着家族性阿尔茨海默氏病从症状发生前阶段一直到诊断的过程,海马和全脑体积如何变化。方法:九个突变携带者在不同的临床阶段(有症状的,轻度的认知障碍或临床阿尔茨海默氏病)进行了连续的临床评估和体积MRI扫描(41次扫描:每位患者3-8范围)。 25名健康对照者进行了连续扫描(54次扫描:每位患者2-4次)以进行比较。我们使用半自动化技术测量了全脑和海马总体积,并对颅内总体积进行了调整。开发了分级模型,以估计突变携带者与对照在疾病被临床诊断时的体积和萎缩率的差异。结果:与对照组相比,突变携带者的海马和全脑萎缩率显着增加,并且这些差异随时间增加。在确诊阿尔茨海默氏病之前,对照组和突变携带者之间海马和全脑萎缩率的差异分别为5.5年和3.5年。在横截面水平上,突变携带者和对照之间的平均海马体积差异在临床诊断前3年变得显着,而平均脑体积的差异仅在诊断前1年才显着。解释:在家族性阿尔茨海默氏病临床发作之前的MRI扫描中可以看到结构变化。萎缩率的纵向测量可以比突变体测量方法早2-3年发现突变携带者与对照之间的差异。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号